Orofacial dyskinesia after moxifloxacin treatment--a case with normal hepatorenal function and review of literature.

Abstract

BACKGROUND:

Orofacial dyskinesia is rarely reported with antibiotics. Among antibiotics, third-generation fluoroquinolones are known to cause movement disorders. We report the first patient who developed orofacial dyskinesia after taking a fourth-generation fluoroquinolone, namely, moxifloxacin.

METHODS:

The patient is a 58-year-old woman who was treated with moxifloxacin for acute bronchitis. She developed orofacial dyskinesia involving the tongue, lips, and facial muscles after treatment.

RESULTS:

Discontinuation of moxifloxacin and treatment with clonidine resulted in significant reduction of orofacial dyskinesia over the period of 8 to 12 weeks. A review of literature shows reports of a variety of involuntary movements with third-generation fluoroquinolones, mostly manifesting in patients with impaired renal and kidney function.

CONCLUSIONS:

The fourth-generation fluoroquinolone moxifloxacin can cause orofacial dyskinesia like third-generation fluoroquinolone antibiotics and in a patient with normal renal and liver function.

• Authors: Shivam Om Mittal, Duarte Goncalves Machado, Bahman Jabbari
• Journal: Clinical neuropharmacology (Clin Neuropharmacol) 2012 Nov-Dec Vol. 35 Issue 6 Pg. 292-4 ISSN: 1537-162X [Electronic] United States
• PMID: 23151468 (Publication Type: Case Reports, Journal Article, Review)

Chemical References

• Anti-Infective Agents
• Aza Compounds
• Fluoroquinolones
• Quinolines
• Moxifloxacin

Topics

• Anti-Infective Agents (adverse effects)
• Aza Compounds (adverse effects)
• Dyskinesia, Drug-Induced (diagnosis, physiopathology)
• Female
• Fluoroquinolones
• Humans
• Kidney Function Tests (methods, trends)
• Liver Function Tests (methods, trends)
• Middle Aged
• Movement Disorders (diagnosis, physiopathology)
• Moxifloxacin
• Quinolines (adverse effects)
• Treatment Outcome